Cardiff Oncology, Inc. announced that Katherine L. Ruffner, M.D., chief medical officer (CMO), will be leaving the company on April 22, 2022, to pursue a new opportunity. Dr. Ruffner will provide Cardiff Oncology with transitional support. Sandra L. Silberman, M.D., Ph.D., who previously acted as a chief medical advisor to the company from June 2017 to July 2021, has agreed to serve as the company's senior medical advisor and oversee its clinical trials and clinical operations team on an interim basis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.5 USD | -6.37% | -15.25% | +68.92% |
May. 02 | Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+68.92% | 112M | |
+34.01% | 51.07B | |
+33.84% | 38.86B | |
-8.02% | 38.78B | |
-8.98% | 26.69B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- CRDF Stock
- News Cardiff Oncology, Inc.
- Cardiff Oncology, Inc. Announces Executive Changes